The survey of more than 400 specialty pharmacists also found that nearly two-thirds of specialty pharmacists report spending more than 15 minutes on the phone to fill one prescription, and 79% of specialty pharmacists seek additional information from clinicians at least three times in an average day.
Specialty medications that treat serious and chronic conditions like cancer, multiple sclerosis and rheumatoid arthritis have complex documentation requirements.
When combined with a manual prior authorisation process, the result is an overwhelming amount of administrative work that gets in the way of pharmacists spending enough time with patients.
In fact, 40% of specialty pharmacists say the process is so burdensome that they feel more like an admin than a pharmacist.
Given the complex nature of specialty medications, this often leads to a seemingly endless cycle of phone calls and faxes with prescribers to obtain necessary information.
In fact, 39% of specialty pharmacists say they seek additional information from their clinician counterparts five times or more each day.
The administrative burden of specialty medications is resulting in increased burnout among care providers, including pharmacists.
The Surescripts survey found that 71% of specialty pharmacists are somewhat, very or extremely stressed at work, and 63% identified prior authorization as a source of stress.
According to a study in the American Journal of Health-System Pharmacy, more than half of health-system pharmacists have a high degree of burnout.
Most specialty pharmacists agree that an automated system would help.
The survey found that 86% of specialty pharmacists say getting more complete information from clinicians would improve patient care, and 56% think streamlined communication, specifically, secure messaging within their workflow, would improve the fulfillment process.
Surescripts partnered with Survata to administer the 33-question online survey to 414 active specialty pharmacists. Their responses were collected February 19–25, 2020.
European Commission approves RINVOQ for severe alopecia areata
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers
argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102
Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Teva and Polpharma Biologics enter global licensing agreement for biosimilar candidate to Ocrevus
United Therapeutics acquires Thymmune Therapeutics to expand regenerative cell therapy pipeline
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
Japan approves Wayrilz for immune thrombocytopenia treatment